Health Condition 1: J988- Other specified respiratory disorders
Conditions
Interventions
Intervention1: manashiladi ghrita along with trikatu curna: Manashiladi Ghrita 10gm bid along with Trikatu churna 2gm empty stomach for 30 days.
Control Intervention1: saptaparna swarasa
pipali churna
Sponsors
All India Institute Of Ayurveda
Eligibility
Inclusion criteria
Inclusion criteria: 3. Having sign and symptoms of Tamak Shwas/ ACOâ?? swasakruchhrata (dyspnoea), kanthodhwansa (speak with difficulty), kasa (cough), ghurghurka sabda ( wheezing /rhonchi) 4. Pulmonologist diagnosed patient of ACO • Post bronchodilator increase of forced expiratory volume in 1 second (FEV1) >= 12% and >= 400 mL, and eosinophilia in sputum in addition to a personal history of asthma. • High total immune globulin E (IgE), personal history of atopy, and a post bronchodilator increase of FEV1 >= 12% and >= 200 mL on >= 2 occasions. • History of evidence of atopy, elevated total IgE, aged >= 40 years, smoking > 10 pack-years, post-bronchodilator FEV1 5. Not undergoing exercise training program or any other lung rehabilitation therapy. 6. BMI 7. Smokers and ex-smoker with smoking history>=10 pack-years. 8. Patient having allergic diseases or any family history of allergic diseases. 9. Ability to demonstrate compliance with handy-inhaler, a salbutamol Meter Dose Inhaler, and the activity monitor; perform acceptable Pulmonary Function Tests; an exercise stress test and can follow study procedures. (Note: GOLD-Global Initiative for Chronic Obstructive Lung Diseases, MRC- Medical Research Council). 10. Vitamin D3 deficient : Serum 25(OH)D <30ng/ml
Exclusion criteria
Exclusion criteria: a. ACOS with life threatening complications like cor-pulmonale, respiratory failure, pneumothorax and polycythemia. b. Any history of previous chronic infectious respiratory disease like tuberculosis, URTI, acute bronchitis, pneumonia. c. Patient taking steroid therapy from long duration (systemic or inhaled corticosteroid) d. Diagnosis of renal or cardiac asthma. e. History of cystic fibrosis. f. Past or current malignancy within 5years. g. Pregnant ladies and lactating mothers. h. History of any adverse drug reactions. i. Patients having positive HIV1 and 2 or positive Hepatitis B. j. Patients having end stage hepatic dysfunction (defined aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 4 times of the upper normal limit) or severe renal dysfunction (defined as S. creatinine > 1.2 mg/dl),severely compromised cardiac function (EF k. Patient with poorly controlled Hypertension ( > 180 / 100 mm Hg). l. BMI >25 kg/m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observed changes in Pulmonary Function Test (Including FEV1, FVC/FEV1) 1.Lungs function status measured by forced expiratory volume in 1 second(FEV1),Mid expiratory flow 75%(MEF 75%),Mid Expiratory flow 25%[Time frame:1month].Timepoint: Observed changes in Pulmonary Function Test (Including FEV1, FVC/FEV1) 1.Lungs function status measured by forced expiratory volume in 1 second(FEV1),Mid expiratory flow 75%(MEF 75%),Mid Expiratory flow 25%[Time frame:1month]. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anthropomertric measurement measured by BMI,changes in quality of lifeTimepoint: Observed changes in Pulmonary Function Test (Including FEV1, FVC/FEV1) 1.Lungs function status measured by forced expiratory volume in 1 second(FEV1),Mid expiratory flow 75%(MEF 75%),Mid Expiratory flow 25%[Time frame:1month]. | — |
Countries
India
Contacts
Public ContactDr Divya Kajaria
ALL INDIA INSTITUTE OF AYURVED
Outcome results
None listed